Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry
Shinya Goto(Tokai University), Dan Atar, Laura Illingworth(Thrombosis Research Institute), Sylvia Haas(TUM Klinikum), A. John Camm(St George's, University of London), Karen S. Pieper(Clinical Research Institute), Helena Domínguez(University of Copenhagen), Samuel Z. Goldhaber(Brigham and Women's Hospital), Hany Ragy, Zhi‐Cheng Jing(Guangdong Academy of Medical Sciences), Hugo Ten Cate(Maastricht School of Management), Giuseppe Ambrosio(University of Perugia), Pantep Angchaisuksiri(Mahidol University), Keith A.A. Fox(University of Edinburgh), Mátyás Keltai, LG Mantovani(IRCCS Istituto Auxologico Italiano), Frank Cools, Seil Oh(Seoul National University Hospital), Harald Darius(Vivantes Klinikum), Jean‐Pierre Bassand(Observatoire des Sciences de l’Univers Terre Homme Environnement Temps Astronomie), David Fitzmaurice(University of Warwick), Gloria Kayani(Thrombosis Research Institute), Pekka Raatikainen, Marianne Brodmann(Medical University of Graz), Bernard J. Gersh(Clinical Research Institute), John W. Eikelboom(Population Health Research Institute), Jørn Dalsgaard Nielsen, Frank Misselwitz, Toon Wei Lim(National University Heart Centre Singapore), lex Spyropoulos(McMaster University), Giancarlo Agnelli(University of Perugia), Sanjay Kakkar(Thrombosis Research Institute), Ramón Corbalán(St. Michael's Hospital), Yukihiro Koretsune(Osaka National Hospital), Petr Janský, Werner Hacke(Heidelberg University), Ajay K. Kakkar(Thrombosis Research Institute), Dayi Hu, Alexander G.G. Turpie(McMaster University), Stuart J. Connolly, Martin van Eickels(Sanofi (Mexico)), Jean‐Yves Le Heuzey, Héctor Luciardi, Freek W.A. Verheugt(OLVG), Shinichi Goto(Tokai University), Antônio Carlos Pereira Barretto(Universidade de São Paulo), J.P.S. Sawhney(Sir Ganga Ram Hospital), Harry Gibbs(Monash University)
Cited by 55
Related Papers
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11.4k
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k